Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Jae H. Park, MD, discusses the impact of agents such as blinatumomab, inotuzumab ozogamicin, and tisagenlecleucel on the treatment of acute lymphoblastic leukemia.

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses managing patients after treatment with chimeric antigen receptor (CAR) T-cell therapy.

Michael J. Mauro, MD, a hematologist and leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center, discusses updates in chronic myeloid leukemia.

Alison J. Moskowitz, MD, clinical director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, discusses the data that led to the approval of brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL).

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the toxicity profile of olaparib (Lynparza) in breast cancer.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses new targets in melanoma.

C. Ola Landgren, MD, PhD, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses the superiority of 3-drug regimens and the next steps in the treatment of patients with multiple myeloma.

Paul A. Hamlin, MD, chief, Basking Ridge Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the importance of the ZUMA-I trial results in the field of B-cell lymphoma.

Renier J. Brentjens, MD, PhD, discusses the emergence of BCMA as a target for CAR T-cell therapy and other next steps for the field.

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the prevalence of BRCA mutations in triple-negative breast cancer (TNBC).

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the promise of GnRH antagonists in prostate cancer.

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the goal of armored chimeric antigen receptor (CAR) T cells.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses side effects with combination therapy in melanoma.

Alterations in DNA damage response and repair genes were associated with an increased response to anti-PD-1/PD-L1 antibodies in patients with metastatic urothelial carcinoma.

Susan F. Slovin, MD, PhD, discusses the multinational PRONOUNCE study and how the results may affect the treatment of patients with prostate cancer.

Anas Younes, MD, Chief of Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the combination of ibrutinib (Imbruvica) plus nivolumab (Opdivo) in non-Hodgkin lymphoma.

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the difference between GnRH antagonists and GnRH agonists.

Larotrectinib (LOXO-101) induced durable responses in patients with TRK fusion–positive solid tumors, according to updated results for the novel pan-TRK inhibitor.

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the necessity of tailored approaches in the treatment of patients with neuroendocrine tumors (NETs).

Advanced interventional pulmonology techniques are revolutionizing the diagnosis and treatment of lung cancer.

Tiffany A. Traina, MD, discusses her experiences with using neratinib and pertuzumab, and shares her excitement on the direction in which the HER2-positive breast cancer field is moving.

William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the progression of surgery in treating patients with metastatic colorectal cancer.

With the advent of the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) in melanoma physicians are no longer using BRAF inhibitors alone, but rather in combination with MEK inhibitors due to the improved efficacy.

Christopher Crane, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the emergence and success of new technologies in the treatment of patients with gastrointestinal (GI) malignancies.

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, explains the case for neoadjuvant therapy in the treatment of kidney cancer.

Treatment with encorafenib and binimetinib improved survival versus single-agent vemurafenib (Zelboraf) in patients with BRAF-mutant advanced, unresectable or metastatic melanoma.

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the toxicities associated with chimeric antigen receptor (CAR) T-cell therapy.

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing clinical trials and recent approvals that will shape the standard of care in the treatment of patients with neuroendocrine tumors (NETs).

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the potential approval of cabozantinib (Cabometyx) in hepatocellular carcinoma (HCC) could affect the treatment landscape in liver cancer.